Synthetic Biology Sovereignty

“The country that learns to program life will write the rules of the next economy — and the next biological weapon.” The strategic imperative to build and control domestic synthetic biology capability.

Executive Summary

Synthetic biology sovereignty describes a state’s capacity to independently design, engineer, and manufacture biological systems — from novel microorganisms producing pharmaceuticals and materials to agricultural organisms engineered for climate resilience — without dependence on foreign platforms, biological databases, gene synthesis providers, or DNA reading and writing infrastructure. As synthetic biology matures from academic research into industrial manufacturing, it is being recognized as a foundational technology sector analogous to semiconductors: the underlying capability that shapes pharmaceutical independence, agricultural biotechnology leadership, defense biological programs, and industrial bioprocess competitiveness simultaneously. The U.S. and China are in direct competition for synthetic biology leadership, with China’s investments in DNA synthesis capacity, biofoundry infrastructure, and biological data collection representing a structured national strategy — while the U.S. responds with its National Biotechnology and Biomanufacturing Initiative.

The Strategic Mechanism

Synthetic biology sovereignty requires control across five layers:

DNA reading (sequencing):

  • Next-generation sequencing is dominated by Illumina (U.S.) globally, but China’s MGI Tech (subsidiary of BGI) is aggressively capturing market share with lower-cost instruments
  • BGI’s global sequencing operations — including through COVID-19 testing — generated biological data at scale that has attracted U.S. national security scrutiny

DNA writing (synthesis):

  • Gene synthesis companies (Twist Bioscience, IDT/Danaher in the U.S.; Sangon, Tsingke in China) produce custom DNA sequences
  • Export controls on gene synthesis technology and biosecurity screening of synthesis orders are active policy debates
  • The Bipartisan Infrastructure Law and CHIPS-equivalent biotech provisions aim to onshore gene synthesis capacity

Biological design software and AI:

  • AlphaFold (DeepMind) has transformed protein structure prediction; biological design AI is the next competitive frontier
  • Large biological foundation models trained on proprietary biological data represent durable intellectual property advantages

Biofoundry infrastructure:

  • Automated biological design-build-test-learn cycles require biofoundry facilities integrating robotics, AI, and analytical instrumentation
  • U.S. national biofoundry network investments versus China’s provincial bioindustry parks represent parallel national infrastructure strategies

Biological data sovereignty:

  • National genomic databases (China’s National Genomics Data Center; UK Biobank; U.S. All of Us) represent strategic assets
  • Export restrictions on human genomic data are being implemented in both the U.S. and China

Market & Policy Impact

  • Pharmaceutical biomanufacturing: COVID-19 exposed U.S. dependence on Chinese API (active pharmaceutical ingredient) production; synthetic biology enables domestic biosynthesis of complex molecules
  • BGI national security actions: The U.S. added BGI and affiliated entities to entity lists and defense contractor blacklists between 2020 and 2024 on biosecurity grounds; U.S. government use of BGI sequencing equipment was restricted
  • Agricultural biotech: Gene-edited crops (using CRISPR) engineered for drought resistance, yield, and nutrient content represent a bioeconomy frontier with food security implications
  • Defense biological programs: Synthetic biology enables development of novel biological agents, enhanced pathogens (in the wrong hands), and bio-detection capabilities — driving U.S. DARPA and DTRA investment
  • Executive Order on Bioeconomy: President Biden’s September 2022 EO on Biotechnology and Biomanufacturing established the first U.S. national bioeconomy strategy, explicitly framed as a competitiveness and security measure

Modern Case Study: BGI, Genomic Data, and the Biosecurity Response, 2020–2025

BGI Genomics — the world’s largest genomic sequencing company by volume — became a focal point of U.S. biosecurity concern following revelations that its prenatal genetic testing products, deployed globally including in the U.S., generated biological data flowing to Chinese state genomic databases under Chinese law requiring domestic data localization. A Reuters investigation in 2021 documented BGI’s collection of fetal genetic data from millions of women globally. The U.S. Defense Department added BGI affiliates to the “Chinese military company” list in 2023. The U.S. data broker rule finalized in 2024 restricted transfers of bulk U.S. genomic data to Chinese entities. Multiple U.S. states and hospital systems removed BGI sequencing equipment from clinical networks. By 2025, the episode had established a precedent: biological data generated by commercial synthetic biology tools constitutes a national security asset, and the entities that accumulate it at scale — whether through COVID testing, prenatal screening, or consumer genomics — are exercising a form of biological intelligence collection.